Bionano Reports First Quarter 2026 Results and Provides a Business Update
Rhea-AI Summary
Bionano (Nasdaq: BNGO) reported Q1 2026 revenue of $6.7 million, up 4% year over year, with consumables revenue of $3.9 million, up 20%. Flow cell sales rose 17% to 8,178. Reported and adjusted gross margin were both 49%, versus 46% in Q1 2025.
Operating expenses fell 2% to $11.1 million, while adjusted operating expense increased 7% to $9.1 million. The company highlighted new CPT reimbursement developments for optical genome mapping and guided Q2 2026 revenue to $7.5–$7.8 million and full-year 2026 revenue to $30–$33 million.
AI-generated analysis. Not financial advice.
Positive
- Q1 2026 revenue grew 4% year over year to $6.7 million
- Consumables revenue increased 20% year over year to $3.9 million
- Flow cell units sold rose 17% year over year to 8,178
- Gross margin improved to 49% from 46% in Q1 2025
- Operating expenses reduced by 2% to $11.1 million
- New CPT codes and fee increases support OGM reimbursement
- Full-year 2026 revenue guidance set at $30–$33 million
Negative
- Adjusted operating expense increased 7% year over year to $9.1 million
News Market Reaction – BNGO
On the day this news was published, BNGO declined 4.80%, reflecting a moderate negative market reaction. Argus tracked a trough of -9.7% from its starting point during tracking. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $699K from the company's valuation, bringing the market cap to $13.86M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
BNGO slipped 0.79% with modestly above-average volume while only one peer (RVP) appeared in momentum scans, moving down without news, indicating today’s setup looks more stock-specific than sector-driven.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 13 | Q3 2025 earnings | Positive | +3.4% | Q3 2025 revenue growth, higher consumables use, and cost reductions. |
| Aug 14 | Q2 2025 earnings | Neutral | -5.3% | Revenue decline offset by stronger gross margin and higher consumables demand. |
| May 14 | Q1 2025 earnings | Neutral | +5.1% | Revenue drop with improving gross margin and significant operating cost cuts. |
| Mar 31 | FY 2024 earnings | Neutral | +11.1% | Lower 2024 revenue but higher margins, growing OGM installs, 2025 guidance. |
| Jan 13 | Prelim FY 2024 | Neutral | -1.6% | Preliminary Q4 and FY 2024 revenue with product launches and financing. |
Across the last five earnings-related releases, Bionano’s stock showed an average move of about 2.53%, with both positive and negative reactions, indicating earnings have produced mixed but generally moderate volatility.
Recent history shows Bionano using earnings updates to highlight revenue trends, margin improvements and cost reductions. Q4 2024 and FY 2024 results emphasized higher gross margins despite revenue declines, while 2025 quarters focused on shifting toward consumables and software, growing OGM system installs, and cutting operating expenses. Multiple earnings reports also reiterated revenue guidance in the $26–32M range and discussed financing plus runway into early 2026. Today’s Q1 2026 release continues that pattern of balancing modest growth with cost control and guidance for $30–33M in 2026 revenue.
Historical Comparison
In the past year, BNGO issued 5 earnings-related updates with an average move of 2.53%, suggesting earnings typically drive moderate, not extreme, price reactions.
Earnings releases show a shift from declining revenue with margin gains toward modest top-line growth, higher consumables usage, and tighter operating expenses, while maintaining revenue guidance around the low-$30M range.
Regulatory & Risk Context
On May 8, 2026, Bionano filed an S-3 shelf to offer up to $400,000,000 in various securities for general corporate purposes, including working capital, R&D, debt repayment and capital expenditures. The shelf is not yet effective and shows 0 usage to date.
Market Pulse Summary
This announcement reports Q1 2026 revenue of $6.7M, up 4% year-over-year, with consumables revenue of $3.9M and gross margin improving to 49%. Flow cell volume rose 17% to 8,178 units while operating expenses declined slightly, and 2026 revenue guidance remains $30–33M. Key context includes new reimbursement tailwinds for OGM CPT codes and a recently filed $400,000,000 shelf, alongside prior disclosures of going-concern uncertainty and the plan to retire secured convertible debt.
Key Terms
optical genome mapping medical
category i cpt code regulatory
clinical lab fee schedule regulatory
secured convertible debt financial
AI-generated analysis. Not financial advice.
Conference call today, May 13, 2026, at 4:30 PM ET
SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the first quarter ended March 31, 2026.
"The Bionano business is healthy, with first quarter results reflecting the continued engagement of our installed base and positive utilization trends across our optical genome mapping (OGM) and VIA software user community," commented Al Luderer, Ph.D., chairman and interim chief executive officer of Bionano. "The evidence base supporting OGM continues to expand across hematologic malignancies, constitutional genetics, and cell and gene therapy applications, and we are seeing global broad-based adoption at leading institutions. We remain convinced that OGM is on a clear and accelerating path to becoming the standard for comprehensive, genome-wide structural variant analysis. Equally important, we are closing in on a meaningful balance sheet milestone - the expected retirement of our secured convertible debt - which will further strengthen our financial position and allow us to direct future capital towards growing our business.”
Q1 2026 Financial Results
For the three-month period ended March 31, 2026, as compared to the same period of 2025:
- Reported total revenue of
$6.7 million , representing an increase of4% from$6.5 million compared to the first quarter of 2025.- Consumables revenue was
$3.9 million , representing an increase of20% compared to the first quarter of 2025.
- Consumables revenue was
- Sold 8,178 nanochannel array flow cells in the first quarter of 2026, representing an increase of
17% over the 6,994 flow cells sold in the first quarter of 2025. - Generated gross margin of
49% , compared to46% for the first quarter of 2025, and adjusted gross margin1 of49% , compared to46% for the first quarter of 2025. - Reduced operating expenses by
2% to$11.1 million and increased adjusted operating expense1 by7% to$9.1 million .
Recent Business Highlights:
- January 1, 2026, a new Category I CPT code (81354) for the use of OGM in cytogenomic genome-wide analysis to detect structural and copy number variations related to constitutional genetic disorders, went effective on the clinical lab fee schedule (CLFS). The new code covers the OGM-Dx™ Postnatal Whole Genome SV and OGM-Dx™ Prenatal Whole Genome SV LDTs and is priced above comparable microarray codes.
- Final 2026 Clinical Lab Fee Schedule reflected a
47% increase in the payment determination for CPT code 81195, covering OGM use in hematologic malignancy analysis, rising from$1,263.53 t o$1,853.22 , effective January 1, 2026. - New publication from Johns Hopkins and MD Anderson Cancer Center in the American Journal of Hematology demonstrating that OGM can significantly outperform traditional analytical methods for detection of structural variations and chromosomal abnormalities in multiple myeloma.
- New publication from Sanford Burnham Prebys Medical Discovery Institute describing use of OGM to detect genomic alterations introduced by gene editing technologies.
- Demonstrated growing utility of OGM in analysis of rare diseases with 28 publications in the first quarter, a
56% increase over the prior year period. - Highlighted advances in optical genome mapping through twelve studies presented at ACMG 2026.
- Hosted the Bionano Symposium 2026 with robust attendance, drawing more than 1,250 registrants across nearly 35 external presentations from 33 different presenters, spanning hematologic malignancies, oncology research, bioprocessing applications, and constitutional genetic disorder research, with leading institutions describing automation of OGM workflows and plans to scale to thousands of samples per year.
2026 Outlook
We anticipate the following results for Q2 and the full year 2026:
- Q2 2026 revenue guidance in the range of
$7.5 t o$7.8 million . - Full year 2026 revenue guidance in the range of
$30 t o$33 million .
Webcast Details
Date: Wednesday, May 13, 2026
Time: 4:30 p.m. Eastern Time
Participant Registration: Registration – Click Here
Webcast: Registration – Click Here
Participants should register at the link above in advance of the call, and then click the webcast link before the call begins. An archived version of the webcast will be available for replay in the Investors section of the Bionano website.
1 “Adjusted gross margin” and “adjusted operating expense” are non-GAAP financial measures. Please refer to the section titled “Adjusted Financial Measures” below for a description of the adjusted financial measures used herein. Reconciliations of adjusted financial measures to the most directly comparable GAAP financial measures are included in the financial tables accompanying this release.
About Bionano
Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through optical genome mapping (OGM) solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. The Company also offers an industry-leading, platform-agnostic genome analysis software solution, and nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the Company also offers OGM-based diagnostic testing services.
For more information, visit www.bionano.com or www.bionanolaboratories.com.
Bionano’s products are for research use only and not for use in diagnostic procedures.
Adjusted Financial Measures
Note: Effective with the fiscal period ended March 31, 2026, the Company renamed certain of its non-GAAP financial measures. Measures previously reported as "non-GAAP gross margin," "non-GAAP operating expense," and other titles using "non-GAAP" are now presented as "adjusted gross margin," "adjusted operating expense," and similar designations, respectively. These title changes are intended solely to simplify the Company’s presentation and align with the nomenclature commonly used by the Company’s peers. The definitions, methodologies, and components underlying each of these measures remain unchanged from prior periods, and no adjustments have been made to the items included in, or excluded from, the calculation of any such measure on account of the title changes. Prior-period amounts and descriptions have been recast to conform to the current-period presentation.
To supplement Bionano’s financial results reported in accordance with U.S. generally accepted accounting principles (GAAP), the Company has provided adjusted gross margin and adjusted operating expense in this press release and the accompanying conference call, each of which is a adjusted financial measure. The most directly comparable GAAP measures to these adjusted financial measures are gross margin, cost of revenue, selling, general and administrative expense, research and development expense, intangible assets and other long-lived assets impairment, restructuring costs and operating expense, each as reported in accordance with GAAP. Adjusted gross margin excludes from gross margin reported in accordance with GAAP: stock-based compensation. Adjusted operating expense excludes from operating expense reported in accordance with GAAP: stock-based compensation, amortization of intangibles, and transaction-related expenses. In addition, our reconciliation table provided at the end of this release contains certain additional adjusted metrics, including adjusted cost of revenue, adjusted selling, general and administrative expense, adjusted research and development expense, adjusted intangible assets and other long-lived assets impairment and adjusted restructuring costs, each with adjustments as presented in the table. Stock-based compensation and certain other items excluded from our adjusted financial measures are recurring expenses for us and are expected to continue in future periods.
Bionano believes that each of these adjusted metrics is useful to investors and analysts as a supplement to its financial information prepared in accordance with GAAP for analyzing the Company’s performance and identifying trends in its business. Bionano uses these adjusted metrics internally to facilitate period-to-period comparisons and analysis of its performance in order to understand, manage and evaluate its business, to make operating decisions, and for forecasting and budgeting. Accordingly, Bionano believes presentation of these adjusted measures allows for greater transparency with respect to key financial metrics it uses in assessing its own operating performance and making operating decisions.
These adjusted financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP measures; should be read in conjunction with the Company’s consolidated financial statements prepared in accordance with GAAP; have no standardized meaning prescribed by GAAP; and are not prepared under any comprehensive set of accounting rules or principles. In addition, from time to time in the future, there may be other items that the Company may exclude for purposes of its adjusted financial measures; and the Company may in the future cease to exclude items that it has historically excluded for purposes of its adjusted financial measures. Likewise, the Company may determine to modify the nature of its adjustments to arrive at its adjusted financial measures. Because of the non-standardized definitions of adjusted financial measures, each adjusted financial measure as used by Bionano in this press release and the accompanying reconciliation table has limits in its usefulness to investors and may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by other companies.
For a reconciliation of adjusted gross margin to gross margin reported in accordance with GAAP and adjusted operating expense to operating expense reported in accordance with GAAP, please refer to the financial tables accompanying this press release.
Forward-Looking Statements of Bionano Genomics
This press release and the accompanying conference call contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations or financial condition, business strategy and plans, and objectives of management for future operations, are forward-looking statements. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our expectations regarding market adoption of our products; our commercial prospects and future financial and operating results; and our ability to meet our stated goals and commercial opportunities, including our full year and first quarter 2026 guidance. Each of these forward-looking statements involves risks and uncertainties. Accordingly, investors and prospective investors are cautioned not to place undue reliance on these forward-looking statements as they involve inherent risk and uncertainty (both general and specific) and should note that they are provided as a general guide only and should not be relied on as an indication or guarantee of future performance. There are a number of important factors that could cause the actual results to differ materially from those expressed in any forward-looking statement made by us. These factors include, but are not limited to: our ability to improve our margins, extend our cash runway and reach a potential pathway to profitability; our ability to retire our debt at maturity; our ability to continue as a going concern as disclosed in our filings with the SEC which requires us to manage costs and obtain significant additional financing to fund our strategic plans and commercialization efforts; our ability to execute on our strategy and achieve our objectives; the impact and utility of our cost savings initiative and our recent financing; our ability to continue to drive OGM (as defined above) adoption by potential customers for routine use in genomic analysis; the impact, or lack thereof, of Category I CPT codes to accelerate or increase the adoption of OGM; continued research, presentations and publications involving OGM and its utility compared to traditional cytogenetics and our technologies; the impact of our Stratys™ system and VIA™ software to increase throughput and simplify analysis of OGM data; our ability to drive adoption of OGM and our technology solutions; our ability to further deploy new products and applications for our technology platforms; our expectations and beliefs regarding future growth of the business and the markets in which we operate; our ability to consummate any strategic alternatives including the risk that if we fail to obtain additional financing we may seek relief under applicable insolvency laws; the size and growth potential of the markets for our products, and our ability to serve those markets; the rate and degree of market acceptance of our products; our ability to manage the growth of our business and integrate acquired businesses; our ability to expand our commercial organization to address effectively existing and new markets that we intend to target; the impact from future regulatory, judicial, and legislative changes or developments in the U.S. and foreign countries; our ability to compete effectively in a competitive industry; the introduction of competitive technologies or improvements in existing technologies and the success of any such technologies; the performance of our third-party contract sales organizations, suppliers and manufacturers; our ability to attract and retain key scientific or management personnel; the accuracy of our estimates regarding expenses, future revenues, reimbursement rates, capital requirements and needs for additional financing; the impact of adverse geopolitical and macroeconomic developments, such as recent and future bank failures, ongoing international conflicts, and related sanctions, regional or global pandemics, inflation, tariffs, increased cost of goods, supply chain issues, and global financial market conditions on our business and operations, as well as the business or operations of our suppliers, customers, manufacturers, research partners and other third parties with whom we conduct business and our expectations with respect to the duration of such impacts and the resulting effects on our business; our ability to realize the anticipated benefits and synergies of our prior and any future acquisitions or other strategic transactions; our ability to attract collaborators and strategic partnerships; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission (“SEC”), including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2025, any subsequently filed Quarterly Reports on Form 10-Q and in other filings subsequently made by us with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise, except as may be required by law.
CONTACT
Investor Relations:
Webb Campbell
Gilmartin Group
+1 (415) 520-5817
IR@bionano.com
| Bionano Genomics, Inc. Condensed Consolidated Balance Sheet (Unaudited) | ||||||||
| (Unaudited) | ||||||||
| March 31, 2026 | December 31, 2025 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 3,425 | $ | 2,990 | ||||
| Investments | 10,980 | 16,279 | ||||||
| Accounts receivable, net | 4,133 | 5,200 | ||||||
| Inventory | 5,307 | 5,448 | ||||||
| Prepaid expenses and other current assets | 4,864 | 5,203 | ||||||
| Restricted investments | 10,266 | 10,266 | ||||||
| Total current assets | 38,975 | 45,386 | ||||||
| Property and equipment, net | 14,040 | 14,847 | ||||||
| Operating lease right-of-use asset | 3,062 | 3,217 | ||||||
| Financing lease right-of-use asset | 3,044 | 3,095 | ||||||
| Intangible assets, net | 3,005 | 4,345 | ||||||
| Other long-term assets | 2,678 | 2,694 | ||||||
| Total assets | $ | 64,804 | $ | 73,584 | ||||
| Liabilities and stockholders’ equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 5,062 | $ | 5,590 | ||||
| Accrued expenses | 3,996 | 5,460 | ||||||
| Contract liabilities | 1,126 | 967 | ||||||
| Operating lease liability | 646 | 697 | ||||||
| Finance lease liability | 246 | 249 | ||||||
| Convertible debentures and High Trail notes payable (at fair value) | 10,152 | 9,979 | ||||||
| Total current liabilities | 21,228 | 22,942 | ||||||
| Operating lease liability, net of current portion | 2,507 | 2,489 | ||||||
| Finance lease liability, net of current portion | 3,463 | 3,480 | ||||||
| Long-term contract liabilities | 143 | 249 | ||||||
| Total liabilities | 27,341 | 29,160 | ||||||
| Stockholders’ equity: | ||||||||
| Preferred stock | — | — | ||||||
| Common stock | 1 | 1 | ||||||
| Additional paid-in capital | 765,373 | 764,026 | ||||||
| Accumulated deficit | (727,923 | ) | (719,620 | ) | ||||
| Accumulated other comprehensive income (loss) | 12 | 17 | ||||||
| Total stockholders’ equity | 37,463 | 44,424 | ||||||
| Total liabilities and stockholders’ equity | $ | 64,804 | $ | 73,584 | ||||
| Bionano Genomics, Inc. Condensed Consolidated Statement of Operations (Unaudited) | ||||||||
| Three Months Ended March 31, | ||||||||
| 2026 | 2025 | |||||||
| Revenue: | ||||||||
| Product revenue | $ | 6,094 | $ | 6,004 | ||||
| Service and other revenue | 593 | 453 | ||||||
| Total revenue | 6,687 | 6,457 | ||||||
| Cost of revenue: | ||||||||
| Cost of product revenue | 3,205 | 3,053 | ||||||
| Cost of service and other revenue | 230 | 466 | ||||||
| Total cost of revenue | 3,435 | 3,519 | ||||||
| Operating expenses: | ||||||||
| Research and development | 3,139 | 2,370 | ||||||
| Selling, general and administrative | 8,010 | 9,033 | ||||||
| Total operating expenses | 11,149 | 11,403 | ||||||
| Loss from operations | (7,897 | ) | (8,465 | ) | ||||
| Other income (expenses): | ||||||||
| Interest income | 223 | 290 | ||||||
| Other income (expense) | (619 | ) | 5,080 | |||||
| Total other income (expense) | (396 | ) | 5,370 | |||||
| Loss before income taxes | (8,293 | ) | (3,095 | ) | ||||
| Provision for income taxes | (10 | ) | (7 | ) | ||||
| Net loss | $ | (8,303 | ) | $ | (3,102 | ) | ||
| Bionano Genomics, Inc. Reconciliation of GAAP to Adjusted Financial Measures (Unaudited) | ||||||||
| Three Months Ended March 31, | ||||||||
| 2026 | 2025 | |||||||
| GAAP gross margin: | ||||||||
| GAAP revenue | $ | 6,687 | $ | 6,457 | ||||
| GAAP cost of revenue | 3,435 | 3,519 | ||||||
| GAAP gross profit | 3,252 | 2,938 | ||||||
| GAAP gross margin % | 49 | % | 46 | % | ||||
| Adjusted gross margin: | ||||||||
| GAAP revenue | $ | 6,687 | $ | 6,457 | ||||
| GAAP cost of revenue | 3,435 | 3,519 | ||||||
| Stock-based compensation expense | (31 | ) | (37 | ) | ||||
| Adjusted cost of revenue | 3,404 | 3,482 | ||||||
| Adjusted gross profit | 3,283 | 2,975 | ||||||
| Adjusted gross margin % | 49 | % | 46 | % | ||||
| GAAP operating expense | ||||||||
| GAAP selling, general and administrative expense | $ | 8,010 | $ | 9,033 | ||||
| Stock-based compensation expense | (561 | ) | (1,300 | ) | ||||
| Intangible asset amortization | (1,340 | ) | (1,340 | ) | ||||
| Transaction related expenses | (100 | ) | (63 | ) | ||||
| Adjusted selling, general and administrative expense | 6,009 | 6,330 | ||||||
| GAAP research and development expense | $ | 3,139 | $ | 2,370 | ||||
| Stock-based compensation expense | (78 | ) | (250 | ) | ||||
| Adjusted research and development expense | 3,061 | 2,120 | ||||||
| Total adjusted operating expense | $ | 9,070 | $ | 8,450 | ||||
